Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds

Advertising today archive

2267 PWToday Stories

Lannett Announces Agreement For Authorized Generic Version Of Toprol-XL®

30 Nov 17

Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an agreement with Aralez Pharmaceuticals Trading DAC, an Irish designated activity company, to become the exclusive distributor in the U.S. of the authorized generic version of Toprol-XL® (Metoprolol Succinate) Extended Release Tablets in 25 mg, 50 mg, 100 mg and 200mg.  For the 12 months ended September 2017, total U.S. sales at Average Wholesale Price (AWP) of Metoprolol Succinate extended release tablets 25 mg, 50 mg, 100 mg and 200 mg were approximately $690 million, according to IMS.  Financial terms were not disclosed.

"Metoprolol Succinate is a widely prescribed medication and will be an important addition to our cardiovascular product offering," said Arthur Bedrosian, chief executive officer of Lannett.  "We expect to launch the product, under the Lannett label, in the near future."

Metoprolol Succinate extended release is a beta-blocker used to treat chest pain (angina), heart failure and high blood pressure.  Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems.

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.